Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 0

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration Statement No. 333-283315

| PROSPECTUS |

<div align='center'>Up to 20,312,500 shares of Common Stock underlying the Series C Warrants

Up to 20,312,500 shares of Common Stock underlying the Series D Warrants

Up to 1,015,625 shares of Common Stock underlying the Placement Agent Warrants

Applied DNA Sciences, Inc.</div>

This prospectus relates to the resale from time
to time, by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling
Stockholders,” of up to an aggregate of 41,640,625 shares of common stock, par value $0.001 per share (the “Common Stock”),
which the selling stockholders (the “Selling Stockholders”) may acquire upon the exercise of outstanding warrants, consisting
of (i) 20,312,500 Series C Warrants (the “Series C Warrants”), (ii) 20,312,500 Series D Warrants
(“Series D Warrants”, and, together with the Series C Warrants, the “Series Warrants”) and (iii) 1,015,625
Placement Agent Warrants (“Placement Agent Warrants”, and together with the Series Warrants, the “Private Placement
Warrants”).

We issued the Series Warrants to the Selling
Stockholders in a private placement concurrent with a registered direct offering (the “Offering”) of 19,247,498 shares of
Common Stock and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,065,002 shares of Common Stock. We issued
the Placement Agent Warrants to the Selling Stockholders pursuant to that certain engagement letter dated August 23, 2024, by and
between the Company and Craig-Hallum Capital Group LLC (“Craig Hallum”).

The exercisability of the Private Placement
Warrants will be available only upon receipt of such stockholder approval (the “Warrant Stockholder Approval”) as may be
required by the applicable rules and regulations of The Nasdaq Stock Market LLC. Each Series C Warrant has an exercise price
of $0.32 per share of Common Stock, will become exercisable upon the first trading day (the “Stockholder Approval Date”)
following the Company’s notice to warrantholders of Warrant Stockholder Approval, and